Information Provided By:
Fly News Breaks for October 7, 2015
AGN
Oct 7, 2015 | 07:00 EDT
JPMorgan analyst Chris Schott believes Allergan's "inexpensive valuation" provides investors with a "compelling buying opportunity." The Botox marker should post high-single/low-double digit topline growth for the "foreseeable future" and has "significant" M&A optionality, Schott tells investors in a research note. He reiterates an Overweight rating on Allergan with a $400 price target. The stock closed yesterday down $6.07 to $272.51.
News For AGN From the Last 2 Days
There are no results for your query AGN